High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631. (Q33339509)

25 July 2017

High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631. (English)

1 reference

25 July 2017

1 reference

1 reference

Kosty MP

1

1 reference

25 July 2017

Herndon JE 2nd

2

1 reference

25 July 2017

Vogelzang NJ

3

1 reference

25 July 2017

Kindler HL

4

1 reference

25 July 2017

Green MR

5

1 reference

25 July 2017

1 November 2001

1 reference

25 July 2017

1 reference

25 July 2017

34

1 reference

25 July 2017

2

1 reference

25 July 2017

289-295

1 reference

Malignant mesothelioma. The University of Minnesota experience

25 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900250-1

7 January 2021

Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900250-1

7 January 2021

Surgical management of malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900250-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900250-1

1 reference

7 January 2021

Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900250-1

7 January 2021

Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900250-1

7 January 2021

Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900250-1

7 January 2021

A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900250-1

7 January 2021

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900250-1

7 January 2021

A phase I-II study of intensive-dose adriamycin for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900250-1

7 January 2021

Cardiac abnormalities in patients with diffuse malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900250-1

7 January 2021

Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900250-1

7 January 2021

10.1016/S0169-5002(01)00250-1

Identifiers

DOI

1 reference

25 July 2017

1 reference